Exscientia to Present at Upcoming Investor Conferences in November

Rhea-AI Summary

Exscientia plc (Nasdaq: EXAI) announced its participation in several upcoming investor conferences in November 2022. Key events include a fireside chat on AI in Drug Discovery at the BofA Securities A.I. and Disruptive Tech Conference on November 9, investor meetings at the Jefferies London Healthcare Conference on November 16, and a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on November 29. Live webcasts will be available on the company's website, with archived replays accessible for 30 days.

OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in November:

• BofA Securities 2022 A.I. and Disruptive Tech Conference. Fireside chat (AI in Drug Discovery) on Wednesday, November 9, 2022, at 12:40 p.m. EST (5:40 p.m. GMT)
• 2022 Jefferies London Healthcare Conference. Management will participate in investor meetings on Wednesday, November 16, 2022, in London, United Kingdom
• 5^th Annual Evercore ISI HealthCONx Conference. Fireside chat on Tuesday, November 29, 2022, at 8:50 a.m. EST (1:50 p.m. GMT)

Live webcasts of the fireside chats will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai. Archived replays of the webcasts will be available for approximately 30 days following the presentation.

About Exscientia
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).

Visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221101005278/en/

Investors:

Sara Sherman

investors@exscientia.ai

Media:

media@exscientia.ai

Source: Exscientia

FAQ

What is the schedule for Exscientia plc at the investor conferences in November 2022?

Exscientia plc will participate in the following: BofA Securities A.I. and Disruptive Tech Conference on November 9, Jefferies London Healthcare Conference on November 16, and Evercore ISI HealthCONx Conference on November 29.

Will Exscientia plc provide webcasts for its investor conference presentations?

Yes, Exscientia will offer live webcasts of its fireside chats, which will be available on their website under the Investors & Media section.

What is Exscientia's focus in drug development?

Exscientia focuses on AI-driven drug discovery, particularly in oncology, and aims to improve patient outcomes through precision medicine.

Where is Exscientia plc headquartered?

Exscientia plc is headquartered in Oxford, England.

How can I access Exscientia's archived webcasts?

Archived replays of Exscientia's webcasts will be available on their website for approximately 30 days following the live presentations.